Organoids in Drug Discovery
Predictive methods are needed to increase the chance of success in your drug programs before clinical trials. Organoids are a beneficial tool in drug discovery and toxicity testing, aiding target discovery, validation, and pre-clinical testing. Organoid models provide a more physiologically relevant cellular composition and tissue structure than standard 2D models, with increased accuracy and higher throughput. Additionally, patient-derived organoids can be used to predict drug toxicity and efficacy, allowing you to make precise and confident decisions to advance your drug candidates.
Learn how organoids can help your drug-discovery workflow below.
Interview: The Role of Organoids and Organ-On-A-Chip Systems in Drug Discovery
Drs Bas Trietsch, Chief Technology Officer at MIMETAS, and Jenna Moccia, Director of Product Management at ƽ Technologies, discuss the challenges that lead pharma companies to adopt advanced in vitro models, such as organoids and organ-on-a-chip, and the benefits they see after incorporating these systems in their research.
Watch Now >-
Intestinal Organoids: Improved Tools and In Vitro Models for Drug DevelopmentIntestiCult™ Organoid Differentiation Medium and IntestiCult™ Organoid Growth Medium enable the differentiation, establishment, and maintenance of intestinal organoid cultures derived from human tissue. In this Innovation Showcase from ISSCR 2021, Martin Stahl demonstrates how these organoids can be used as cutting-edge tools for drug development, highlighting new assays and protocols optimized to work with both 3D and 2D cultures. He will also compare the use of human intestinal organoids with common intestinal cell lines for analyzing drug responses.
